Data from: Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy

Diane E. Frank, Frederick J. Schnell, Cody Akana, Saleh H. El-Husayni, Cody A. Desjardins, Jennifer Morgan, Jay S. Charleston, Valentina Sardone, Joana Domingos, George Dickson, Volker Straub, Michela Guglieri, Eugenio Mercuri, Laurent Servais & Francesco Muntoni
Objective To report safety, pharmacokinetics, exon 53 skipping, and dystrophin expression in golodirsen-treated patients with Duchenne muscular dystrophy (DMD) amenable to exon 53 skipping. Methods Part 1 was a randomized, double-blind, placebo-controlled, 12-week dose titration of once-weekly golodirsen; Part 2 is an ongoing, open-label evaluation. Safety and pharmacokinetics were primary and secondary objectives of Part 1. Primary biological outcome measures of part 2 were blinded exon skipping and dystrophin protein production on muscle biopsies (baseline,...

Registration Year

  • 2020
    1

Resource Types

  • Dataset
    1

Affiliations

  • Agostino Gemelli University Polyclinic
    1
  • Hôpital Armand Trousseau
    1
  • Newcastle University
    1
  • University College London
    1
  • University of London
    1
  • Sarepta Therapeutics (United States)
    1